MedPage Today: Combination treatment promising for certain leukemia patients
UC expert comments on new study
A combination of low-intensity chemotherapy and an antibody-drug conjugate drug showed promise in a phase 2 trial for older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukemia (ALL).
MedPage Today highlighted the study, and patients in the study had a "significant improvement" in their five-year progression-free survival compared to historical data for this patient set, according to the study's authors.
Emily Curran, MD, medical director of the University of Cincinnati Cancer Center Clinical Trials Office and assistant professor of Internal Medicine in UC's College of Medicine, authored a corresponding commentary on the study, published in The Lancet Hematology.
The study "provides impressive results, with survival outcomes that far exceed historic survival data in older adults with acute lymphocytic leukemia," Curran wrote in the commentary.
Read the MedPage Today article.
Featured photo at top: Dr. Emily Curran examines specimens using a microscope in her lab. Photo/Colleen Kelley/UC Marketing + Brand.
Related Stories
Local couple uses royalties from children's books to give gifts to kids in need
December 15, 2025
A local couple has found a unique way to give back to those in need this holiday season. Vic and Laura Troha wrote two children's books together, and this year, they are using the proceeds to buy Christmas gifts for Hamilton County foster kids. The couple are both graduates of the University of Cincinnati's College of Allied Health Sciences and met the day they graduated.
The hottest toys this holiday season
December 15, 2025
Local 12 turned to Lindner College of Business associate professor-educator of marketing Roseann Hassey to explain what’s got the trendiest items flying off the shelves.
Leukemia and Drug Development Lab trains the next generation of scientific researchers
December 15, 2025
From undergraduate student workers to members of the Physician Scientist Training Program (PSTP), trainees in UC's Leukemia and Drug Development Lab shared their experiences of in-depth, hands-on training that contribute to real-world discoveries.